Belite Bio, Inc. ADR ( (BLTE) ) has provided an announcement.
On February 26, 2025, Belite Bio announced that the Data Safety Monitoring Board recommended the continuation of their Phase 3 DRAGON trial of Tinlarebant for adolescent Stargardt disease without modifications, following an interim analysis. This decision, based on the trial’s safety and efficacy data, suggests a stable visual acuity in subjects and supports the drug’s potential regulatory approval, marking a significant milestone in addressing a disease with no approved treatments.
More about Belite Bio, Inc. ADR
Belite Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for degenerative retinal diseases with significant unmet medical needs, such as Stargardt disease type 1 and Geographic Atrophy in advanced dry age-related macular degeneration. Their lead candidate, Tinlarebant, is an oral therapy aimed at reducing toxin accumulation in the eye, currently undergoing Phase 3 and Phase 2/3 trials.
YTD Price Performance: -14.30%
Average Trading Volume: 40,090
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.71B
See more data about BLTE stock on TipRanks’ Stock Analysis page.